[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shashi Dadlani\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100639400","polynucleotides-and-hyaluronic-acid-vs-enamel-matrix-proteins-in-the-treatment-of-intrabony-defects-100639400",false,"NCT07589959","Polynucleotides and Hyaluronic Acid vs Enamel Matrix Proteins in the Treatment of Intrabony Defects","Polynucleotides and Hyaluronic Acid vs Enamel Matrix Derivative Proteins in the Treatment of Intrabony Defects: A Randomized Controlled Clinical Trial","PN-HAVSEMPIND","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Non-smokers or light smokers (fewer than 10 cigarettes per day)\n* No diabetes or well-controlled diabetes\n* At least one infrabony periodontal defect ≥ 3 mm in depth\n* Periodontal pocket depth ≥ 6 mm at baseline (after initial treatment)\n* Full-mouth plaque and bleeding scores ≤ 20%, ≤15% at re-evaluation\n* Ability and willingness to attend follow-up visits for 1, 3, and 5 years\n* Teeth included in the study must be healthy from an endodontic point of view or properly root-treated\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients with weakened immune systems or significant systemic diseases\n* Heavy smokers (more than 10 cigarettes per day)\n* Full-mouth plaque or bleeding scores \\>20%, \\>15%\n* Current alcohol or drug abuse\n* Patients who have received periodontal treatment within the last 6 months\n* Patients unwilling or unable to attend follow-up visits required for the study","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare two periodontal regenerative treatments in adults with Stage III or IV periodontitis and infrabony periodontal defects ≥3 mm.\n\nThe study aims to determine whether hyaluronic acid and polynucleotides (Regenfast®) combined with bovine bone graft material (Bio-Oss®) provides similar or improved periodontal regeneration compared with enamel matrix derivative proteins (Emdogain®) combined with Bio-Oss®.\n\nResearchers will evaluate:\n\n* Periodontal healing and bone regeneration\n* Changes in probing depth, clinical attachment level, gingival recession, and tooth mobility\n* Radiographic bone fill\n* Survival of treated teeth after 1, 3, and 5 years\n\nParticipants will:\n\n* Receive initial periodontal treatment and oral hygiene instruction\n* Undergo clinical and radiographic evaluation\n* Receive minimally invasive periodontal regenerative surgery under local anesthesia\n* Be randomly assigned to receive either Regenfast® + Bio-Oss® or Emdogain® + Bio-Oss®\n* Attend follow-up visits with periodontal examinations and radiographs over 5 years",[27,28,29,30],"Periodontal Bone Loss","Periodontal Defect","Periodontitis Stage III","Periodontitis Stage IV",[32,33,34,35],"Infrabony Periodontal Defects","Polynucleotides","Hyaluronic Acid","Enamel Matrix Proteins","NOT_YET_RECRUITING","2026-05-11",{"date":39,"type":40},"2026-05-15","ACTUAL",{"date":42,"type":21},"2026-05",{"date":44,"type":21},"2031-07-30",{"name":46,"class":47},"Shashi Dadlani","OTHER",""]